Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic
agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of
femoroacetabular impingement and labral tear.
We believe that giving Fisetin, a senolytic agent, will improve the benefit of PRP by
eliminating senescent cells and senescence-associated secretory phenotype (SASP), known to
exist in PRP. The main objectives of this study are to determine if pre- and post-operative
administration of a senolytic agent will improve the beneficial effects of PRP when used in
conjunction with surgical treatment of FAI and/or labral tear, to determine whether pre- and
postoperative administration of Fisetin is associated with adverse events, and to determine
if pre- and post-operative administration of Fisetin leads to a decrease in systemic
senescence, serum SASP, and fibrotic markers.
Patients suffering from femoroacetabular impingement and labral tear, who are planning to
undergo hip arthroscopy combined with standard of care intra-operative PRP injection and
post-operative losartan administration will be recruited from the clinical practice of the
Principal Clinical Investigator or his designee at The Steadman Clinic (TSC).